

### **Amendments To The Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-33. (canceled)

34. (Previously presented) A composition comprising a dosage of 5 mg/kg to 10 mg/kg of 1,2-Bis-(methylsulfonyl)-1-(2-chloroethyl)-2-(methyaminocarbonyl)-hydrazine (VNP40101M) and a dosage of about 50 mg/kg of cytarabine, wherein the VNP40101M and cytarabine produce synergistic effects when used in combination in treating tumor.

35. (Previously presented) A composition comprising a dosage of 5 mg/kg to 10 mg/kg of VNP40101M and a dosage of about 70 mg/kg of fludarabine, wherein the VNP40101M and fludarabine produce synergistic effects when used in combination in treating tumor.

36. (Previously presented) A method of treating tumor in a subject, comprising the step of administering to the subject 5 mg/kg to 10 mg/kg of VNP40101M and about 50 mg/kg cytarabine, wherein the amounts of VNP40101M and cytarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or cytarabine individually.

37. (Previously presented) The method of claim 36, wherein the tumor is solid malignant tumor, leukemia or lymphoma.

Applicants : KING et al.  
USSN : 10/593,217  
Filed : September 15, 2006  
Examiner : Ganapathy Krishnan

Atty. Dkt. No. : 891-A-PCT-US  
Art Unit : 1623  
Date of Amendment : July 10, 2009  
Page : 4

38. (Previously presented) The method of claim 36, wherein VNP40101M and cytarabine are administered concurrently or sequentially.
39. (Previously presented) The method of claim 36, wherein VNP40101M and cytarabine are administered intravenously, subcutaneously, or orally.
40. (Previously presented) The method of claim 37, wherein the leukemia is acute myelogenous leukemia.
41. (Currently amended) The method of claim 36, A method of treating tumor in a subject, comprising administering to the subject wherein VNP40101M is administered between 100 and 1000 mg/m<sup>2</sup> of VNP40101M and between 500 and 5000 mg/m<sup>2</sup> cytarabine is administered between 500 and 5000 mg/m<sup>2</sup>, wherein the amounts of VNP40101M and cytarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or cytarabine individually.
42. (Previously presented) The method of claim 36, wherein the subject is a human.
43. (Previously presented) A method of treating tumor in a subject, comprising the step of administering to the subject 5 mg/kg to 10 mg/kg VNP40101M and about 70 mg/kg fludarabine, wherein the amounts of VNP40101M and fludarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or fludarabine individually.

Applicants : KING et al.	Atty. Dkt. No.	: 891-A-PCT-US
USSN : 10/593,217	Art Unit	: 1623
Filed : September 15, 2006	Date of Amendment	: July 10, 2009
Examiner : Ganapathy Krishnan	Page	: 5

44. (Previously presented) The method of claim 43, wherein the tumor is solid malignant tumor, leukemia or lymphoma.
45. (Previously presented) The method of claim 43, wherein VNP40101M and fludarabine are administered concurrently or sequentially.
46. (Previously presented) The method of claim 43, wherein VNP40101M and fludarabine are administered intravenously, subcutaneously, or orally.
47. (Previously presented) The method of claim 44, wherein the leukemia is acute myelogenous leukemia.
48. (Previously presented) The method of claim 43, wherein the subject is a human.